- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.08. | Orchestra BioMed reports positive data on blood pressure therapy | 1 | Investing.com | ||
| 26.08. | Orchestra BioMed meldet positive Studiendaten zu Blutdrucktherapie | 2 | Investing.com Deutsch | ||
| 26.08. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology | 1 | GlobeNewswire (USA) | ||
| 20.08. | BTIG stuft Orchestra BioMed ab: Bedenken wegen Kapitalerhöhung und Zeitplanverzögerungen | 2 | Investing.com Deutsch | ||
| ORCHESTRA BIOMED Aktie jetzt für 0€ handeln | |||||
| 20.08. | Orchestra BioMed stock rating downgraded to Neutral from Buy by BTIG | 1 | Investing.com | ||
| 14.08. | Orchestra BioMed: Positive Studiendaten für Herztherapie bei schwacher Aktienperformance | 2 | Investing.com Deutsch | ||
| 14.08. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction | 1 | GlobeNewswire (USA) | ||
| 12.08. | Orchestra BioMed GAAP EPS of -$0.50, revenue of $0.84M | 1 | Seeking Alpha | ||
| 12.08. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates | 901 | GlobeNewswire (Europe) | Secured over $111 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by over $71 million in committed... ► Artikel lesen | |
| 12.08. | Orchestra BioMed Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.08. | Orchestra BioMed rises as trial for antihypertensive drug expands | 1 | Seeking Alpha | ||
| 08.08. | FDA approves expansion to Orchestra BioMed pacemaker trial | 1 | MassDevice | ||
| 08.08. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility | 118 | GlobeNewswire (Europe) | FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study ("BACKBEAT study"), resulting in an estimated more than 24-fold increase in the... ► Artikel lesen | |
| 05.08. | Orchestra BioMed brings in $111M through Medtronic, Ligand deals | 2 | MassDevice | ||
| 05.08. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings | 228 | GlobeNewswire (Europe) | $56.2 million in proceeds from completed public offering and concurrent private equity purchase by Medtronic and Ligand$55 million in proceeds and funding commitments from royalty-based, non-dilutive... ► Artikel lesen | |
| 01.08. | Orchestra BioMed prices $40M offering, amends Medtronic deal | 5 | MassDevice | ||
| 01.08. | Orchestra BioMed announces pricing of $40 million public offering | 1 | Seeking Alpha | ||
| 01.08. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Pricing of $40 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 01.08. | Orchestra BioMed secures $70 million from Ligand and Medtronic | 3 | Investing.com | ||
| 31.07. | Orchestra BioMed announces public offering of common stock | 1 | Investing.com |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MINERALYS THERAPEUTICS | 28,700 | -0,55 % | Jefferies raises Mineralys Therapeutics stock price target to $26 from $15 | ||
| QIAGEN | 40,015 | -0,44 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 47,040 | -0,40 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| EVOTEC | 5,830 | +0,69 % | EQS-DD: Evotec SE: Dr. Christian Wojczewski, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
27.08.2025 / 15:03... ► Artikel lesen | |
| BEAM THERAPEUTICS | 18,790 | +15,21 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 11,150 | +0,41 % | ARS Pharma drops 9% as Lupin files application for generic neffy | ||
| BIONTECH | 86,20 | -0,35 % | BioNTech Aktie: Kurssturz? - Circus, Commerzbank, Evotec, Puma und SFC Energy im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,710 | +1,07 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
| VERA THERAPEUTICS | 22,860 | +1,11 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| VALNEVA | 3,838 | +8,73 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH
29.08.2025 / 16:48 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,045 | -0,90 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 60,52 | +3,12 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update | Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the... ► Artikel lesen | |
| BB BIOTECH | 36,600 | +2,66 % | EQS-PVR: BB BIOTECH AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: BB BIOTECH AG
BB BIOTECH AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,840 | -0,67 % | Harmony Biosciences Holdings, Inc.: Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress | Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30... ► Artikel lesen | |
| DYNE THERAPEUTICS | 13,570 | +0,52 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen |
Das Unternehmen ORCHESTRA BIOMED HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,09 % bei einem Aktienkurs von 2,710 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ORCHESTRA BIOMED HOLDINGS INC finden Sie auf Wallstreet Online.